CME/CE
This accredited activity is jointly provided by Partners for Advancing Clinical Education (Partners) and DKBmed.
Acknowledgement
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
All activity content and materials are developed solely by the planning committee members and faculty presenters.
Target Audience
The target audience includes ophthalmologists and retina specialists attending the live and enduring education with a focus on the Midwest.
Educational Objectives
Upon completion of this activity, participants should be able to:
- Discuss consequences of delayed treatment of neovascular AMD.
- Discuss consequences of delayed treatment of diabetic retinopathy.
- Describe efficacy and safety of newer anti-VEGF treatments for nAMD.
- Evaluate the benefits of newly available treatment anti-VEGF options for DR and DME.
Disclosures
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty / Presenter Reported Financial Relationship
| Faculty | Conflicts of Interest |
| Dr. Sumit Sharma, MD
Cleveland Clinic Cole Eye Institute Vice Chair, Integrated Surgical Institute Cleveland Clinic Lerner College of Medicine of Case Western Reserve University |
Consultant, Advisor, Speaker: Alimera, Abbvie, Apellis, Bausch and Lomb, Clearside, Eyepoint, Genentech/Roche, Iveric Bio, Kodiak, Merck, Regeneron, RegenXBio, Ripple, Volk, Zeiss
Researcher: Acelyrin, Gilead, Genentech/Roche, Santen, IONIS, Kodiak |
| Christopher Babiuch, MD
Vice Chair; Safety, Quality and Patient Experience Cleveland Clinic Primary Care Institute |
None |
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and DKBmed LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
Please note, MOC credit is reported on a monthly basis.
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.
To claim and receive MOC credits, learners must email [email protected] and provide:
- ABIM ID number
- First and last name
- Degree and specialty
- DOB (month and day)
- Activity completion date
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 ANCC contact hours.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating and receiving CME/CE credit for this activity.
Request for Credit
- Release date: March 26, 2026
- Expiration date: March 25, 2027
Estimated time to complete the activity: 45 minutes
Hardware & Software Requirements
To access activities, users will need:
- A computer with an internet connection
- An HTML5 compliant web browser or Internet Explorer 8 (and higher)
Contact Information
For additional information about the accreditation of this activity, please visit https://partnersed.com